Alteogen Inc
KOSDAQ:196170
Alteogen Inc
Cash from Operating Activities
Alteogen Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Operating Activities
₩21.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Operating Activities
₩745.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cash from Operating Activities
-₩128B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cash from Operating Activities
₩133.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Cash from Operating Activities
-₩3.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-62%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash from Operating Activities
₩122.7B
|
CAGR 3-Years
28%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
Glance View
In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.
See Also
What is Alteogen Inc's Cash from Operating Activities?
Cash from Operating Activities
21.7B
KRW
Based on the financial report for Sep 30, 2024, Alteogen Inc's Cash from Operating Activities amounts to 21.7B KRW.
You don't have any saved screeners yet